Table 3.
Association of LCACs and clinical parameters in all participants.
| Age | H&Y | UPDRS-III | LED | |||||
|---|---|---|---|---|---|---|---|---|
| r | p-Value | r | p-Value | r | p-Value | r | p-Value | |
| AC(12:0) | −0.293 | 0.115 | 0.128 | 0.499 | 0.240 | 0.200 | 0.287 | 0.123 |
| AC(12:1)−1 | −0.115 | 0.541 | 0.179 | 0.343 | 0.141 | 0.457 | 0.272 | 0.145 |
| AC(16:1) | −0.199 | 0.291 | 0.0476 | 0.802 | 0.124 | 0.510 | 0.132 | 0.485 |
| AC(16:2) | −0.110 | 0.562 | 0.185 | 0.326 | 0.153 | 0.417 | 0.0969 | 0.610 |
LCACs: long-chain acylcarnitines, H&Y: Hoehn and Yahr stage, UPDRS: Unified Parkinson’s Disease Rating Scale, LED: levodopa equivalent dose. p-Value obtained by Spearman’s rank correlation coefficient.